The Cooper Companies, Inc. $COO Shares Sold by WINTON GROUP Ltd

WINTON GROUP Ltd trimmed its position in shares of The Cooper Companies, Inc. (NASDAQ:COO) by 41.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 48,454 shares of the medical device company’s stock after selling 34,830 shares during the quarter. WINTON GROUP Ltd’s holdings in Cooper Companies were worth $3,971,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in COO. Wellington Management Group LLP increased its stake in shares of Cooper Companies by 332.9% during the third quarter. Wellington Management Group LLP now owns 6,184,992 shares of the medical device company’s stock worth $424,043,000 after acquiring an additional 4,756,178 shares during the period. Diamond Hill Capital Management Inc. grew its position in Cooper Companies by 479.6% during the fourth quarter. Diamond Hill Capital Management Inc. now owns 3,287,837 shares of the medical device company’s stock worth $269,471,000 after buying an additional 2,720,594 shares during the period. JANA Partners Management LP acquired a new position in Cooper Companies during the third quarter worth about $166,917,000. Capital World Investors grew its position in Cooper Companies by 25.7% during the third quarter. Capital World Investors now owns 10,551,592 shares of the medical device company’s stock worth $723,417,000 after buying an additional 2,159,233 shares during the period. Finally, Ameriprise Financial Inc. grew its position in Cooper Companies by 98.8% during the second quarter. Ameriprise Financial Inc. now owns 3,388,413 shares of the medical device company’s stock worth $241,120,000 after buying an additional 1,683,561 shares during the period. 24.39% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have weighed in on COO shares. Barclays upped their target price on shares of Cooper Companies from $98.00 to $103.00 and gave the stock an “overweight” rating in a research report on Friday, March 6th. Wells Fargo & Company restated a “sell” rating and set a $66.00 target price (down from $82.00) on shares of Cooper Companies in a research report on Friday. Rothschild & Co Redburn lowered shares of Cooper Companies from a “buy” rating to a “neutral” rating and set a $85.00 target price on the stock. in a research report on Wednesday, March 4th. Piper Sandler set a $86.00 target price on shares of Cooper Companies and gave the stock an “overweight” rating in a research report on Monday, June 1st. Finally, Wall Street Zen upgraded shares of Cooper Companies from a “hold” rating to a “buy” rating in a research report on Saturday, February 28th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, Cooper Companies has a consensus rating of “Hold” and a consensus target price of $82.64.

Cooper Companies Stock Up 8.6%

Shares of NASDAQ COO opened at $67.34 on Friday. The Cooper Companies, Inc. has a 12-month low of $58.89 and a 12-month high of $89.83. The company has a market capitalization of $13.14 billion, a PE ratio of 57.07, a price-to-earnings-growth ratio of 1.74 and a beta of 0.87. The company has a debt-to-equity ratio of 0.22, a current ratio of 1.34 and a quick ratio of 0.79. The firm’s 50-day moving average is $65.09 and its two-hundred day moving average is $74.52.

Cooper Companies (NASDAQ:COO) last announced its quarterly earnings results on Thursday, June 4th. The medical device company reported $1.21 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.10 by $0.11. Cooper Companies had a net margin of 5.57% and a return on equity of 10.85%. The company had revenue of $1.08 billion for the quarter, compared to the consensus estimate of $1.06 billion. During the same quarter in the prior year, the firm earned $0.96 earnings per share. The company’s revenue for the quarter was up 7.9% compared to the same quarter last year. Cooper Companies has set its FY 2026 guidance at 4.580-4.660 EPS. Equities analysts anticipate that The Cooper Companies, Inc. will post 4.63 EPS for the current fiscal year.

Cooper Companies News Roundup

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: Cooper Companies posted better-than-expected Q2 results, with EPS of $1.21 topping estimates of $1.10 and revenue of $1.08 billion beating forecasts, while sales rose 7.9% year over year. CooperCompanies Announces Second Quarter 2026 Results
• Positive Sentiment: Management said it reached agreements to resolve substantially all claims tied to the prior fertility media recall, reducing a major legal overhang and supporting investor confidence in the company’s outlook. QuiverQuant article
• Positive Sentiment: Needham reaffirmed a Buy rating on COO and lowered its price target to $86, still implying meaningful upside from current levels. TipRanks analyst update
• Positive Sentiment: Stifel, Baird, and JPMorgan all cut price targets but kept constructive ratings, suggesting analysts see the report as solid even after valuation resets. Benzinga analyst update
• Neutral Sentiment: The company guided FY2026 EPS to $4.58-$4.66, slightly around consensus, which helps confirm expectations but does not point to a major near-term surprise. Earnings report transcript
• Negative Sentiment: JPMorgan lowered its price target on COO from $80 to $71 and kept a Neutral rating, reflecting more cautious expectations despite the stock’s recent strength. JPMorgan price target update

Cooper Companies Profile

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.